Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Carcinoma in Situ × Cystoscopy × Clear all

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 5 Urinary Bladder Diseases 1 Non-Muscle Invasive Bladder Neoplasms 1 Neoplasms 1 Carcinoma, Transitional Cell 1 Carcinoma in Situ 1

Interventions

dodecyl maltoside 2 toripalimab 1 pembrolizumab 1 durvalumab 1 apaziquone 1 Mitomycin 1 Imiquimod 1 Gemcitabine 1 Docetaxel 1 Cystoscopy 1 Biopsy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02901548 2022-07-29

Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated

17 enrolled 9 charts

Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma in Situ

Data powered by HemOnc (CC BY 4.0) Colophon ⚡